My laboratory is developing and evaluating new imaging agents for whole-body imaging and intraoperative imaging. Our main focus is to selectively label malignant growths in vivo to allow for their detection, treatment, and removal. We believe that the next generation of selective imaging agents will result in better and more-sensitive detection of tumor tissues, which will ultimately benefit patient treatment.


Emmetiere F, Irwin C, Viola-Villegas NT, Longo V, Cheal SM, Zanzonico P, Pillarsetty N, Weber WA, Lewis JS, Reiner T (2013) 18F-labeled-Bioorthogonal Liposomes for In Vivo Targeting. Bioconjugate chemistry 24:1784–1789.

Reiner T, Lacy J, Keliher EJ, Yang KS, Ullal A, Kohler RH, Vinegoni C, Weissleder R (2012) Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia (New York, NY) 14:169–177 – Cover.

Reiner T, Keliher EJ, Earley S, Marinelli B, Weissleder R (2011) Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method. Angew Chem Int Ed Engl 50:1922–1925.

Reiner T, Thurber G, Gaglia J, Vinegoni C, Liew CW, Upadhyay R, Kohler RH, Li L, Kulkarni RN, Benoist C et al. (2011) Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog. Proc Natl Acad Sci U S A 108:12815–12820.

Reiner T, Kohler RH, Liew CW, Hill JA, Gaglia J, Kulkarni RN, Weissleder R (2010) Near-infrared fluorescent probe for imaging of pancreatic Beta cells. Bioconjug Chem 21:1362–1368.